Pipeline
Our pipeline incorporates precision diagnostics with alpha and beta-emitting radionuclide therapies.
Our Pipeline
Our lead diagnostic and therapeutic programs are progressing beyond preclinical evaluation to first-in-human studies
Our lead diagnostic and therapeutic programs are progressing beyond preclinical evaluation to first-in-human studies
Our lead diagnostic and therapeutic programs are progressing beyond preclinical evaluation to first-in-human studies
Starting first-in-human
INDICATION
THERAPY RESISTANT SOLID TUMOURS
NTx#
NTx -010
NTx -011
NTx -043
APPLICATION
DIAGNOSTIC
THERAPEUTIC
NEXT GEN
THERAPEUTIC
DISCOVERY
PRECLINICAL
PHASE 0/1
INDICATION
THERAPY RESISTANT SOLID TUMOURS
NTx#
NTx -010
NTx -011
NTx -043
APPLICATION
DIAGNOSTIC
THERAPEUTIC
NEXT GEN
THERAPEUTIC
DISCOVERY
PRECLINICAL
PHASE 0/1
INDICATION
THERAPY RESISTANT SOLID TUMOURS
NTx#
NTx -010
NTx -011
NTx -043
APPLICATION
DIAGNOSTIC
THERAPEUTIC
NEXT GEN
THERAPEUTIC
DISCOVERY
PRECLINICAL
PHASE 0/1
INDICATION
THERAPY RESISTANT SOLID TUMOURS
NTx#
NTx -010
NTx -011
NTx -043
APPLICATION
DIAGNOSTIC
THERAPEUTIC
NEXT GEN
THERAPEUTIC
DISCOVERY
PRECLINICAL
PHASE 0/1
Connect with us
Email us, and keep updated on our clinical trial pipeline on LinkedIn.
Connect with us
Email us, and keep updated on our clinical trial pipeline on LinkedIn.
© 2025 Nuclide Therapeutics, All rights reserved
© 2025 Nuclide Therapeutics, All rights reserved
© 2025 Nuclide Therapeutics, All rights reserved